<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39400953</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Imaging the immune sequelae of infection with SARS-CoV-2 in nonhuman primates by using two nanobody PET-tracers.</ArticleTitle><Pagination><StartPage>e29956</StartPage><MedlinePgn>e29956</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29956</ELocationID><Abstract><AbstractText>Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) impacts multiple anatomical sites. Whether this is due to the virus itself or is a secondary effect caused by the influx and activation of immune cells is not known. Positron emission tomography (PET) with immunoglobulins can provide insights into which sites and cells are activated in a living animal. Our aim is to use two nanobodies as tools to monitor (1) the distribution of antigen presenting cells (APC) by virtue of their Mafa-DR expression profile, (2) virus-infected cells and viral particles using a nanobody against the SARS-CoV-2 spike protein. Two [<sup>89</sup>Zr]-labeled nanobodies that target the SARS-CoV-2 spike protein and major histocompatability complex (MHC) class II antigens (Mafa-DR), respectively, are used to monitor their distribution during an experimental SARS-CoV-2 infection in a nonhuman primate model. Scans are obtained before infection and on Day 3 and 10 post infection (pi) in two macaques each. The [<sup>89</sup>Zr]anti-SARS-CoV-2 spike nanobody localized to SARS-CoV-2-associated lung lesions and the nasal mucosa, while the [<sup>89</sup>Zr]anti-human leukocyte antigen (HLA)-DR nanobody was predominantly found in non-affected lung tissue after infection. We also detected, pi, upregulation of the Mafa-DR signal, indicative of recruitment of professional APCs, in the superior sagittal sinus. [<sup>89</sup>Zr]-labeled nanobodies show recruitment of macrophages/monocytes in non-lesional lung tissue in cynomolgus macaques after experimental infection with SARS-CoV-2, as well as accumulation of the spike protein in both lung lesions and the nasal mucosa during infection. These results show the possibility of in vivo monitoring the quality and quantity of immune responses during the initial stages of an infection.</AbstractText><CopyrightInformation>© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koopman</LastName><ForeName>Gerrit</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Biomedical Primate Research Centre (BPRC), Rijswijk, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhoeven</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mooij</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biomedical Primate Research Centre (BPRC), Rijswijk, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acar</LastName><ForeName>Roja F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Biomedical Primate Research Centre (BPRC), Rijswijk, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harmand</LastName><ForeName>Thibault</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cerberus Therapeutics, Cambridge, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flanagan</LastName><ForeName>Laney</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cerberus Therapeutics, Cambridge, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakker</LastName><ForeName>Jaco</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biomedical Primate Research Centre (BPRC), Rijswijk, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Böszörményi</LastName><ForeName>Kinga P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Biomedical Primate Research Centre (BPRC), Rijswijk, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bontrop</LastName><ForeName>Ronald E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Biomedical Primate Research Centre (BPRC), Rijswijk, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, Theoretical Biology and Bioinformatics, Utrecht University, Utrecht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langermans</LastName><ForeName>Jan A M</ForeName><Initials>JAM</Initials><AffiliationInfo><Affiliation>Biomedical Primate Research Centre (BPRC), Rijswijk, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Population Health Sciences, Unit Animals in Science and Society, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ploegh</LastName><ForeName>Hidde L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verschoor</LastName><ForeName>Ernst J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Biomedical Primate Research Centre (BPRC), Rijswijk, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vugts</LastName><ForeName>Danielle J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pishesha</LastName><ForeName>Novalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cerberus Therapeutics, Cambridge, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stammes</LastName><ForeName>Marieke A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-4261-6535</Identifier><AffiliationInfo><Affiliation>Biomedical Primate Research Centre (BPRC), Rijswijk, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>European Virus Archive GLOBAL (EVA-GLOBAL)</Agency><Country /></Grant><Grant><GrantID>871029</GrantID><Agency>European Union's Horizon 2020</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061905">Single-Domain Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061905" MajorTopicYN="Y">Single-Domain Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000938" MajorTopicYN="N">Antigen-Presenting Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">PET‐CT</Keyword><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">nanobody</Keyword><Keyword MajorTopicYN="N">nonhuman primates</Keyword><Keyword MajorTopicYN="N">nuclear medicine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>11</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39400953</ArticleId><ArticleId IdType="doi">10.1002/jmv.29956</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Nieuwland JM, Nutma E, Philippens IHCHM, et al. Longitudinal positron emission tomography and postmortem analysis reveals widespread neuroinflammation in SARS‐CoV‐2 infected rhesus macaques. J Neuroinflammation. 2023;20:179.</Citation></Reference><Reference><Citation>Madden PJ, Arif MS, Becker ME, et al. Development of an in vivo probe to track SARS‐CoV‐2 infection in rhesus macaques. Front Immunol. 2021;12:810047.</Citation></Reference><Reference><Citation>Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID‐19: a post‐mortem study. Lancet Microbe. 2020;1:e245‐e253.</Citation></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. Short‐term and long‐term rates of postacute sequelae of SARS‐CoV‐2 infection: a systematic review. JAMA Network Open. 2021;4:e2128568.</Citation></Reference><Reference><Citation>Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long‐COVID. Trends Immunol. 2022;43:268‐270.</Citation></Reference><Reference><Citation>Priyanka COP, Choudhary OP, Singh I. Protective immunity against COVID‐19: unravelling the evidences for humoral vs. cellular components. Travel Med Infect Dis. 2021;39:101911.</Citation></Reference><Reference><Citation>Juengling FD, Maldonado A, Wuest F, Schindler TH. Identify. quantify. Predict. Why immunologists should widely use molecular imaging for coronavirus disease 2019. Front Immunol. 2021;12:568959.</Citation></Reference><Reference><Citation>Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: concept, design, and applications. Chem Rev. 2020;120:3787‐3851.</Citation></Reference><Reference><Citation>Kleynhans J, Sathekge MM, Ebenhan T. Preclinical research highlighting contemporary targeting mechanisms of radiolabelled compounds for PET based infection imaging. Semin Nucl Med. 2023;53:630‐643.</Citation></Reference><Reference><Citation>Boszormenyi KP, Stammes MA, Fagrouch ZC, et al. The Post‐Acute phase of SARS‐CoV‐2 infection in two macaque species is associated with signs of ongoing virus replication and pathology in pulmonary and extrapulmonary tissues. Viruses. 2021;13:1673.</Citation></Reference><Reference><Citation>Finch CL, Crozier I, Lee JH, et al. Characteristic and quantifiable COVID‐19‐like abnormalities in CT‐ and PET/CT‐imaged lungs of SARS‐CoV‐2‐infected crab‐eating macaques (Macaca fascicularis). bioRxiv. 2020. doi:10.1101/2020.05.14.096727</Citation></Reference><Reference><Citation>Muñoz‐Fontela C, Dowling WE, Funnell SGP, et al. Animal models for COVID‐19. Nature. 2020;586:509‐515.</Citation></Reference><Reference><Citation>Cleary SJ, Pitchford SC, Amison RT, et al. Animal models of mechanisms of SARS‐CoV‐2 infection and COVID‐19 pathology. Br J Pharmacol. 2020;177:4851‐4865.</Citation></Reference><Reference><Citation>Neil JA, Griffith M, Godfrey DI, et al. Nonhuman primate models for evaluation of SARS‐CoV‐2 vaccines. Expert Rev Vaccines. 2022;21:1055‐1070.</Citation></Reference><Reference><Citation>Stammes MA, Lee JH, Meijer L, et al. Medical imaging of pulmonary disease in SARS‐CoV‐2‐exposed non‐human primates. Trends Mol Med. 2022;28:123‐142.</Citation></Reference><Reference><Citation>Kosyreva A, Dzhalilova D, Lokhonina A, Vishnyakova P, Fatkhudinov T. The role of macrophages in the pathogenesis of SARS‐CoV‐2‐associated acute respiratory distress syndrome. Front Immunol. 2021;12:682871.</Citation></Reference><Reference><Citation>Merad M, Martin JC. Pathological inflammation in patients with COVID‐19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355‐362.</Citation></Reference><Reference><Citation>Boumaza A, Gay L, Mezouar S, et al. Monocytes and macrophages, targets of severe acute respiratory syndrome coronavirus 2: the clue for coronavirus disease 2019 immunoparalysis. J Infect Dis. 2021;224:395‐406.</Citation></Reference><Reference><Citation>Huot N, Planchais C, Rosenbaum P, et al. SARS‐CoV‐2 viral persistence in lung alveolar macrophages is controlled by IFN‐γ and NK cells. Nature Immunol. 2023;24:2068‐2079.</Citation></Reference><Reference><Citation>Hanke L, Sheward DJ, Pankow A, et al. Multivariate mining of an alpaca immune repertoire identifies potent cross‐neutralizing SARS‐CoV‐2 nanobodies. Sci Adv. 2022;8:eabm0220.</Citation></Reference><Reference><Citation>Mooij P, Koopman G, Mortier D, et al. Pandemic swine‐origin H1N1 influenza virus replicates to higher levels and induces more fever and acute inflammatory cytokines in cynomolgus versus rhesus monkeys and can replicate in common marmosets. PLoS One. 2015;10:e0126132.</Citation></Reference><Reference><Citation>Islam A, Pishesha N, Harmand TJ, et al. Converting an Anti‐Mouse CD4 monoclonal antibody into an scfv positron emission tomography imaging agent for longitudinal monitoring of CD4(+) T cells. The J Immunol. 2021;207:1468‐1477.</Citation></Reference><Reference><Citation>Rashidian M, Ingram JR, Dougan M, et al. Predicting the response to CTLA‐4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. 2017;214:2243‐2255.</Citation></Reference><Reference><Citation>Rashidian M, Wang L, Edens JG, et al. Enzyme‐Mediated modification of Single‐Domain antibodies for imaging modalities with different characteristics. Angew Chem Int Ed. 2016;55:528‐533.</Citation></Reference><Reference><Citation>Tölgyesi B, Bakker J, Nagy K, Meijer L, van Geest L, Stammes MA. Refined acquisition of high‐resolution thorax CTs in macaques by free breathing. Lab Anim. 2021;55:551.</Citation></Reference><Reference><Citation>Van Elssen CHMJ, Rashidian M, Vrbanac V, et al. Noninvasive imaging of human immune responses in a human xenograft model of Graft‐Versus‐Host disease. J Nucl Med. 2017;58:1003‐1008.</Citation></Reference><Reference><Citation>Mooij P, García‐Arriaza J, Pérez P, et al. Poxvirus MVA expressing SARS‐CoV‐2 S protein induces robust immunity and protects rhesus macaques from SARS‐CoV‐2. Front Immunol. 2022;13:845887.</Citation></Reference><Reference><Citation>Yan Q, Li P, Ye X, et al. Longitudinal peripheral blood transcriptional analysis reveals molecular signatures of disease progression in COVID‐19 patients. J Immunol. 2021;206:2146‐2159.</Citation></Reference><Reference><Citation>Meijer L, Böszörményi KP, Bakker J, et al. Novel application of [(18)F]DPA714 for visualizing the pulmonary inflammation process of SARS‐CoV‐2‐infection in rhesus monkeys (Macaca mulatta). Nucl Med Biol. 2022;112‐113:1‐8.</Citation></Reference><Reference><Citation>Hartman AL, Nambulli S, McMillen CM, et al. SARS‐CoV‐2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and shedding of infectious virus from both respiratory and gastrointestinal tracts. PLoS Pathog. 2020;16:e1008903.</Citation></Reference><Reference><Citation>Philippens I, Boszormenyi KP, Wubben JAM, et al. Brain inflammation and intracellular alpha‐synuclein aggregates in macaques after SARS‐CoV‐2 infection. Viruses. 2022;14:776.</Citation></Reference><Reference><Citation>Rustenhoven J, Drieu A, Mamuladze T, et al. Functional characterization of the dural sinuses as a neuroimmune interface. Cell. 2021;184:1000‐1016.e27.</Citation></Reference><Reference><Citation>Makris S, de Winde CM, Horsnell HL, Cantoral‐Rebordinos JA, Finlay RE, Acton SE. Immune function and dysfunction are determined by lymphoid tissue efficacy. Dis Model Mech. 2022;15:dmm049256.</Citation></Reference><Reference><Citation>Upadhyay AA, Viox EG, Hoang TN, et al. TREM2(+) and interstitial‐like macrophages orchestrate airway inflammation in SARS‐CoV‐2 infection in rhesus macaques. Nat Commun. 1914;2023:14.</Citation></Reference><Reference><Citation>Volkmann A, Koopman G, Mooij P, et al. A capsid virus‐like particle‐based SARS‐CoV‐2 vaccine induces high levels of antibodies and protects rhesus macaques. Front Immunol. 2022;13:857440.</Citation></Reference><Reference><Citation>Meinhardt J, Streit S, Dittmayer C, Manitius R, Radbruch H, Heppner FL. The neurobiology of SARS‐CoV‐2 infection. Nat Rev Neurosci. 2024;25:30‐42.</Citation></Reference><Reference><Citation>Buzhdygan TP, DeOre BJ, Baldwin‐Leclair A, et al. The SARS‐CoV‐2 spike protein alters barrier function in 2D static and 3D microfluidic in‐vitro models of the human blood‐brain barrier. Neurobiol Dis. 2020;146:105131.</Citation></Reference><Reference><Citation>Cheon IS, Li C, Son YM, et al. Immune signatures underlying post‐acute COVID‐19 lung sequelae. Sci Immunol. 2021;6:eabk1741.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>